Rocket Pharmaceuticals Inc. has announced new inducement equity incentive awards for its newly-hired Chief Medical Officer, Dr. Syed Rizvi. The compensation package includes a nonstatutory stock option to purchase up to 383,854 shares of Rocket common stock, 283,018 restricted stock units (RSUs), and an additional 62,893 RSUs. The stock option and the main RSU grant each feature a three-year vesting schedule, with one-third vesting after the first year and the remainder vesting quarterly over the following two years. The additional RSUs vest in two equal installments over two years. The exercise price for the stock options is set at the closing price on the date of the grant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251010643440) on October 10, 2025, and is solely responsible for the information contained therein.